Drug Profile
Monoclonal antibody MRK-16
Alternative Names: Anti-P-glycoprotein monoclonal antibody MRK-16Latest Information Update: 03 Jul 2002
Price :
$50
*
At a glance
- Originator Aventis
- Developer Nonindustrial source
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 22 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma
- 07 Mar 1995 Preclinical development for Cancer in Japan (Unknown route)
- 07 Mar 1995 Preclinical development for Cancer in USA (Unknown route)